QR kód

Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition

Direct Oral Anticoagulants (DOACs) have revolutionized the treatment of thromboembolic disorders, offering targeted, effective, and safer alternatives to traditional anticoagulants like heparins and vitamin K antagonists (VKAs). Despite their benefits, DOACs have drawbacks, including an increased ri...

Celý popis

Uloženo v:
Hlavní autoři: Hisham A. Badreldin, Nada Alsuhebany, Mohammed Alzahrani, Abdulmajeed M. Alshehri, Maha Aldoughaim, Saleh Alqifari, Omar Yassin, Lama Alfehaid, Tariq Alqahtani
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2024-01-01
Edice:Current Research in Pharmacology and Drug Discovery
Témata:
Thromboembolic disorders
Atrial fibrillation
Novel Anticoagulant
Abelacimab
On-line přístup:http://www.sciencedirect.com/science/article/pii/S2590257124000063
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky